Explore the full 2022 list of德赢提款快速公司最具创新性的公司，528个组织正在努力重塑其业务，行业和更广泛的文化。我们已经选择了在52个类别的倡议中产生最大影响的公司，包括最具创新性的公司生物技术，，，，设计，，，，andconsumer goodscompanies.
经过一年的疫苗和Covid-19的治疗方法，制药行业的创新今年有些平凡，这是一种很好的方式。迫切治疗或更糟的疾病最终得到了解决。同时，公司开始重新定义医学的含义。像药丸一样，软件开始治疗身体疾病。是的，公司继续找到帮助预防Covid-19的方法。
所有的制药公司都认可德赢提款快速公司的list of the 10 most innovative medicine and therapeutics companies obtained breakthroughs by taking a creative approach to how they think about drugs. GlaxoSmithKline worked with the Gavi Vaccine Alliance to put its malaria vaccine Mosquirix through clinical trials—a vaccine that took decades to develop, test, and now distribute. Experts estimate that it will put a sizable dent in malaria infection in regions where the disease is endemic.
AstraZeneca worked feverishly to develop preventative monoclonal antibodies to help immunocompromised folk fend off COVID-19. Meanwhile, Mithra Pharmaceuticals designed a birth control pill that (finally!) prioritized women’s health through reducing side effects. Another set of companies created therapeutics that challenged the idea of what medicine can be. Akili Interactive, which went public this year via SPAC, got FDA approval for its all-digital treatment for ADHD. Another company, Hinge Health, is using physical therapy, coaching, and wearables to reduce musculoskeletal pain—no opioids necessary. Big Health is offering patients with insomnia and anxiety therapy without the therapist. All these companies used innovative thinking to bring health care to more people than it’s ever been able to reach before.
1. GlaxoSmithKline
For swatting malaria with its new vaccine that was decades in the making
超过35年的研究葛兰素史克came to fruition last fall when the World Health Organization recommended a wide rollout in sub-Saharan Africa of the pharma company’s Mosquirix, the world’s first malaria vaccine and the first vaccine for a parasitic disease. It has been shown, alongside seasonal anti-malaria efforts, to be 70% effective at减少严重的疟疾和儿童住院，他在2020年占460,000人死亡。“谁在工具箱中寻找另一个工具，以与使用床网，喷雾和抗疟药结合使用，”该公司首席全球卫生官托马斯·布鲁尔（Thomas Breuer）说。GSK已为试点计划运送了超过400万剂的疫苗，大约已经管理了270万剂，并且将提供多达1500万剂的剂量，其剂量将以比成本高出5％的价格出售。
Glaxosmithkline在第31位World’s 50 Most Innovative Companies。
2. viatris
用于创建第一个由FDA批准的可互换生物仿制药用于胰岛素
To bring down the notoriously high cost of insulin,ViaTris，一家制药公司，成立于2020年（辉瑞公司成立的Medicines Arm Upjohn和仿制药公司Mylan之间合并的结果）与印度生物技术公司合作Biocon生物制剂为了将近乎相同的版本带到美国，结果是Semgle，食品药品监督管理局于2021年批准了该胰岛素的所谓生物仿制药，使其成为FDA有史以来首次互换治疗性的。如今，ViaTris Markets既是Semglee又是这种胰岛素生物仿制药的品牌版本，以及一个非品牌版本，比领先的胰岛素品牌Lantus的价格低65％。（两层定价系统反映了保险公司偏爱更高成本的药物的共同做法。
3. Mithra Pharmaceuticals
For developing a plant-based oral contraceptive for women with fewer side effects
比利时生物技术公司密特拉，专注于开发妇女健康的药品，并于2021年获得了植物性避孕药，Nextstellis以及正在分发该药物的Mayne Pharma的植物性避孕药。关键创新是使用Estetrol，这是一种天然体内的雌激素形式，不太可能引起乳腺癌，这是雌激素促成药丸的罕见风险。除了对乳腺组织产生较小的影响外，该药物还与其他口服避孕药相比，突破性出血，痤疮和身体变化较少以及对性驱动的影响较小。最后，由于Estetrol是基于植物的，因此它更容易分解，并且在水道中没有像其他雌激素那样发现。这使得避孕不仅对女性更好，而且对环境更好。
4. VIIV医疗保健
为了曾经每两个月注射以治疗艾滋病毒
This year,viiv推出了Cabenuva，这是治疗艾滋病毒的曾经每两个月注射。这种方案可以取代许多艾滋病毒感受的药丸每天的药物，从本质上讲，它为患有这种疾病的含义创造了新的范式。根据大约有120万人在美国患艾滋病毒的人the U.S. Department of Health and Human Services。FDA最近还批准了VIIV的Apretude作为一个每两个月的一次注射，用于预防前预防。
5.阿斯利康
用于为最易感人士开发预防性COVID-19
一部分将有助于将Covid-19从大流行转变为地方性疾病的部分原因（这种疾病总是存在，如流感，并以可预测的速度传播）是无数疗法和预防措施的发展。今年，食品和药物管理局授权阿斯利康暴露前预防治疗称为Evusheld。这些长效的单克隆抗体为已经有或有望对现有的Covid-19-19疫苗产生不良反应的严重免疫功能低下的人提供了一种疫苗替代品。在试验中，接受者的发展风险降低了77％，使其成为可行的治疗方法，可帮助保护特别脆弱的群体。
6.大健康
用于开发数字版本的认知行为疗法
数字健康干预措施即将成为大生意，并且大健康is at the forefront. The company has been working on developing fully digital experiences for solving some of the most pernicious issues in mental health, such as sleep loss and anxiety. The company’s sleep assistance app has a 70% efficacy rate and is used by companies like Delta and, selectively, in major healthcare entities, including the U.K. National Health Service. In 2021, the Scottish National Health Service agreed to roll out Big Health’s digital therapeutics for insomnia and anxiety to its entire population. Patients can download the app themselves or get a referral from their general practitioner.
7. scynexis
For developing the first non-azole treatment for vaginal yeast infections
过度使用一类称为硫唑的抗真菌剂，通常是为治疗阴道酵母菌感染的规定，导致了抗药性。为了解决抗真菌抗性的问题，scyxisdeveloped an entirely new class of fungicide: triterpenoid antifungal, which doctors can prescribe when first-line azole treatments don’t work. Approved by the FDA in June and launched in September, Brexafemme is the first in this class and the first antifungal medication approved in more than two decades.
8.铰链健康
For developing an online platform for treating musculoskeletal pain
Physicians are looking for an alternative to opioids for pain management, especially for musculoskeletal pain.铰链健康结合运动疗法和数字教练，通过与雇主和健康计划的关系来治疗其1300万成员的肌肉骨骼疼痛。今年，该公司发布了一项大规模研究的数据，该数据表明，参与者在12周的护理中的疼痛平均会改善68％。它还收购了两家公司ENSO，这是一种使用电刺激来减轻疼痛的可穿戴设备，而WRNCH是一家使用计算机视觉测量运动的公司。这两项收购将有助于该公司将其数字健康平台与患者的生活经验融合在一起。
9.安进
用于治疗以前不可治疗的非小细胞肺癌的子集。
Amgen’sLumakras，，，，which received Food and Drug Administration approval in 2021, treats lung cancer tumors with a specific genetic mutation that accounts for a quarter of all non-small cell lung cancers. The drug is the culmination of four decades worth of research into how to target the kras oncogene, a gene that is prone to mutation and until recently, believed to be untargetable with drugs. In trials, 36% of patients with this specific tumor mutation saw their tumor destroyed entirely; another 58% saw the size of their tumors reduced. Of those two groups, neither had recurrent cancer for at least six months. The drug marks a breakthrough for these patients.
10. Akili Interactive
用于开发多动症的数字治疗
多年，Akili互动一直在努力创建一种用于治疗注意力缺陷多动障碍的数字游戏。去年，该公司获得了食品和药物管理局的批准，以销售其游戏，作为治疗性。今年，该公司筹集了1.6亿美元的推出。该节目于今年夏天推出了一项新的研究，以吹捧其功效（在每周五天进行比赛五天之后，8至12岁的儿童中有68％的行为改善了行为的临床改善）。截至11月，该公司正在与900名开处方Endevorrx的医生合作。